Literature DB >> 9168793

Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury.

X L Ma1, B L Lopez, G L Liu, T A Christopher, F Gao, Y Guo, G Z Feuerstein, R R Ruffolo, F C Barone, T L Yue.   

Abstract

Previous studies have shown that glutathione (GSH) plays a central role in the protection against peroxynitrite (ONOO-) toxicity. The present study evaluated the changes of the GSH cytoprotective system against ONOO- in hypercholesterolemia and determined the effects of carvedilol, a beta-blocker with free radical-scavenging activity, on these hypercholesterol-induced changes. New Zealand White rabbits were fed either a normal diet, a high-cholesterol diet, or a high-cholesterol diet supplemented with either carvedilol or propranolol. Eight weeks later, the rabbits were killed, and the thoracic aortas were isolated. Total GSH content of aortic tissue, vasorelaxation response of aortic rings to exogenous ONOO-, No regeneration from ONOO- by aortic homogenate, and ONOO(-)-induced aortic tissue injury were examined. Hypercholesterolemia decreased tissue GSH content (0.52 +/- 0.08 versus 0.86 +/- 0.04 mumol/g in control, P < .01), attenuated the vasorelaxation response to ONOO- (40 +/- 4.1% versus 76 +/- 3.2%, P < .01), reduced NO regeneration from ONOO- (387 +/- 40 versus 662 +/- 51 pmol, P < .01), and potentiated ONOO(-)-induced vascular tissue injury (37 +/- 4.4% versus 14 +/- 2.6% of increase in lactate dehydrogenase release after 3-morpholinosydnonimine exposure, P < .01). Treatment of the hypercholesterolemic rabbits with carvedilol, but not propranolol, significantly preserved tissue GSH content (0.79 +/- 0.05 mumol/g, P < .01 versus nontreated hypercholesterolemic rabbits), restored the vasorelaxation to ONOO- (61 +/- 2%, P < .01), increased NO regeneration from ONOO- (583 +/- 39 pmol, P < .01), and attenuated ONOO(-)-induced tissue injury (19 +/- 1.8%, P < .01). These results suggest that hypercholesterolemia impairs the GSH-mediated detoxification mechanism against ONOO- and renders the vascular tissue more susceptible to oxidative injury. Carvedilol, a novel vasodilating beta-blocker with antioxidant activity, significantly preserved this self-defense system and protected tissue from oxidant injury.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168793     DOI: 10.1161/01.res.80.6.894

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  Induction of glutathione synthesis by oxidized low-density lipoprotein and 1-palmitoyl-2-arachidonyl phosphatidylcholine: protection against quinone-mediated oxidative stress.

Authors:  Douglas R Moellering; Anna-Liisa Levonen; Young-Mi Go; Rakesh P Patel; Dale A Dickinson; Henry Jay Forman; Victor M Darley-Usmar
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

2.  Decreased aortic glutathione levels may contribute to impaired nitric oxide-induced relaxation in hypercholesterolaemia.

Authors:  T Adachi; R A Cohen
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

3.  L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease.

Authors:  J A Vita; B Frei; M Holbrook; N Gokce; C Leaf; J F Keaney
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

4.  Sulforaphane attenuates the development of atherosclerosis and improves endothelial dysfunction in hypercholesterolemic rabbits.

Authors:  George S G Shehatou; Ghada M Suddek
Journal:  Exp Biol Med (Maywood)       Date:  2015-10-20

Review 5.  Role of oxidative stress and nitric oxide in atherothrombosis.

Authors:  Edith Lubos; Diane E Handy; Joseph Loscalzo
Journal:  Front Biosci       Date:  2008-05-01

Review 6.  Delivery of Antioxidant and Anti-inflammatory Agents for Tissue Engineered Vascular Grafts.

Authors:  Kenyatta S Washington; Chris A Bashur
Journal:  Front Pharmacol       Date:  2017-09-21       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.